Neuronasal is a subsidiary of ATAI that aims to reduce post-concussion injury by novel patented nose-to-brain drug delivery. Although the company is not specifically about psychedelics, the parent company is and IP may be shared between them.
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates